MIPS # PIMSH 10 Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs

MEASURE DESCRIPTION

Percentage of patients tested for Hepatitis B prior to receiving anti-CD20 targeting treatment, including rituximab, ofatumumab, and obinutuzumab; patients testing positive for Hepatitis B receive prophylactic treatment.

Relevance to Value Based Care

Patients who previously had hepatitis B are at high risk for HBV infection or HBV reactivation after receiving treatment with rituximab, ofatumumab, or obinutuzumab.  Hepatitis B reactivation is an avoidable condition, and quality measure monitoring with appropriate patient intervention should help reduce the rate of Hepatitis B reactivation.

 Numerator

Patients screened for Hepatitis B (including surface antigen and core antibody) prior to treatment; if screening is positive, patient receives prophylactic treatment.

 Denominator

All patients 18 years or older who have a qualifying visit during the measurement period and received anti-CD20 therapy during the measurement period.

 Exclusion/Exceptions

• Patients participating in a clinical trial at any time.

• Active Hepatitis B.

• Patient refused screening.

 Scoring

Up to 10 points

 RESOURCES